The CCDC152 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HeLa cell line, engineered to disrupt the coiled-coil domain-containing protein 152 (CCDC152) gene. This loss-of-function model enables systematic investigation of CCDC152 within the context of cervical carcinoma biology, without implying monoclonal selection or complete gene inactivation. The polyclonal format preserves the genetic diversity inherent in CRISPR-edited populations, making it suitable for functional genomics screens and pathway analysis where pooled genotypes provide robust phenotypic readouts.
The host HeLa cell line, originated from a human cervical adenocarcinoma with HPV18 integration, exhibits a hypertriploid karyotype and serves as a canonical epithelial model in cancer research, drug screening, and fundamental cell biology. Its well-characterized growth properties, signaling networks, and genetic tractability make it an ideal chassis for knockout studies, particularly in delineating the functions of poorly annotated genes such as CCDC152. The epithelial origin and malignant phenotype of HeLa cells provide a physiologically relevant platform for exploring mechanisms of tumorigenesis and therapeutic resistance.
CCDC152 encodes a coiled-coil domain-containing protein predicted to mediate protein-protein interactions, potentially via homodimerization, and is implicated in the MECOM (EVI1) transcriptional regulatory pathway. MECOM is a zinc finger transcription factor with known roles in cell growth control and oncogenesis, and CCDC152 may function as an interacting factor or co-regulator within MECOM-associated complexes. Although its precise molecular mechanism remains uncharacterized, the observed interaction suggests that CCDC152 could modulate transcriptional programs governing proliferation and survival, particularly in cancers such as gallbladder and connective tissue malignancies where these pathways are perturbed.
In HeLa cells, which exhibit aberrant MECOM expression and downstream signaling, disruption of CCDC152 allows deconvolution of its contribution to the MECOM-regulated transcriptome and phenotypic outcomes. This model is especially valuable for dissecting how coiled-coil domain interactions influence transcriptional networks driving cancer hallmarks, including unchecked proliferation and apoptosis evasion. Because HeLa cells are amenable to high-throughput perturbation studies, this polyclonal knockout pool is a versatile tool for investigating gene function in a well-defined cervical cancer background, with potential translational insights into MECOM-driven malignancies.
Researchers can employ these CCDC152 knockout cells in a range of downstream assays, including Western blotting for CCDC152, RT-qPCR, and RNA-seq to assess transcriptomic changes, as well as functional assays such as MTT/CCK-8 for proliferation, transwell migration/invasion assays, and Annexin V apoptosis profiling. Co-immunoprecipitation and reporter gene assays for MECOM activity further enable mechanistic dissection of protein interactions and transcriptional effects. This polyclonal model seamlessly integrates into cancer biology, protein-protein interaction studies, and functional genomics workflows, providing a robust loss-of-function system for hypothesis-driven research. For additional information or customized cell engineering services, please contact Ascent Research.
